Brenig Therapeutics

Brenig Therapeutics will present its Hybrid AI drug discovery platform at Keystone Symposia, highlighting AI-driven approaches for CNS drug development.

Brenig Therapeutics shared preclinical data for its LRRK2 inhibitor for Parkinson’s disease at the ACS Spring 2024 Conference.

Brenig Therapeutics appoints Megan McGill, MD, PhD, as Chief Executive Officer to lead development of therapies for neurodegenerative diseases.

Brenig Therapeutics announces a $65 million Series A financing to advance its Parkinson’s disease pipeline, including BT-267 and BT-409 programs.

Brenig Therapeutics develops small-molecule therapies for neurodegenerative diseases, including LRRK2 inhibitors for Parkinson’s disease.

Brenig Therapeutics presents Phase 1 trial data for its experimental therapy **BT-267** at the **American Academy of Neurology (AAN) 2026 Annual Meeting**. The findings stem from an ongoing study involving healthy volunteers, evaluating the brain-penetrant small molecule designed for neurodegenerative disease treatment. The presentation occurs during the conference in Chicago, Illinois, scheduled for April 18–22, 2026.

Apr 2026Brenig TherapeuticsNews article

Brenig Therapeutics presents interim Phase 1 trial data for **BT-267**, its brain-penetrant LRRK2 inhibitor, at the **AD/PD 2026** conference. The company highlights early safety and pharmacokinetic findings from ongoing trials targeting neurologic diseases. Brenig also provides updates on **BT-409**, its NLRP3 inhibitor program, though specifics remain undisclosed.

Mar 2026Brenig TherapeuticsNews article

Brenig Therapeutics begins a first-in-human clinical trial of **BT-409**, a brain-selective inhibitor targeting the **NLRP3 inflammasome**, a protein complex linked to neurodegenerative diseases. The company also reports progress in its **BT-267** program, a brain-optimized therapy for **LRRK2**, a genetic target in Parkinson’s disease. Both compounds represent small-molecule approaches to treating neurological disorders.

Jan 2026BioSpaceNews article

Brenig Therapeutics appoints Megan McGill, M.D., Ph.D., as Chief Executive Officer. She leads the clinical-stage biotech firm developing AI-driven small-molecule therapies for neurodegenerative diseases. McGill also joins Brenig’s Board of Directors.

Oct 2025Brenig TherapeuticsNews article